ETI41

Overview

ETI41 is an orally active, selective TLR inhibitor that targets the nucleoside-binding Site I on TLR7 ( IC 50 = 0.63 μM) and TLR9 ( IC 50 = 0.16 μM), sparing surface TLRs (including TLR1/TLR2, TLR2/TLR6, TLR4 and TLR5). ETI41 potently inhibits endosomal TLR-mediated pro-inflammatory signaling with nanomolar activity in cellular, biophysical and in vivo assays. ETI41 suppresses the expression of inflammation-associated genes and effectively ameliorates symptoms in mouse models of psoriasis, and systemic lupus erythematosus (SLE). ETI41 can be used for autoimmune and inflammatory diseases research.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > NF-κB | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > ERK | Products > Signaling Pathways > JNK | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Interleukin Related | Products > Signaling Pathways > Toll-like Receptor (TLR) | Products > Signaling Pathways > p38 MAPK | Products > Signaling Pathways > TNF Receptor

Product Information

• Catalog No.: HY-178166
• CAS No.: 2773474-99-8
• Molecular Formula: C19H30N4
• Molecular Weight: 314.47
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source